News & Views
Lab-ready facility jump-starts CDMO operation in Swiss Biotech Cluster
Oct 13 2021
Early Autumn saw the launch of ten23 health®, a globally operating contract development and manufacturing organization (CDMO), supporting biotech start-ups and pharma companies with development of safe injectable biopharmaceutical drugs for patients.
Led by experts with a proven track record in pharmaceutical product design and development, coupled with an extensive global pharma network, the company offers holistic design and development services, building development roadmaps, de-risking strategies and on-going support.
Prof. Dr. Hanns-Christian Mahler, Chief Enabling Officer (CEO) of ten23 health, said: “There is a significant unmet need in the life sciences market. The number and complexity of molecules and novel therapeutic modalities are increasing. Medical research is facing growing challenges with respect to the stability, usability and consistent manufacturing of medicines.
“Our comprehensive offering will allow our clients to focus on the medicine and the patient, whilst leveraging our pharmaceutical expertise and knowledge to plan and de-risk product development to enable commercialisation with speed, quality and success. Our partners will benefit from shorter development timelines, higher probability of technical success and ultimately stronger market positioning as a result.”
The company moved onto the Rosental campus “Rosental Mitte” in Basel, Switzerland, taking over a fully operational lab and office building from Elanco. The building includes around 4’000 square meters of lab and office space providing a work environment for 150 FTEs.
Kaspar Sutter, member of the Government of the Canton of Basel-Stadt and Head of the Department of Economic, Social and Environmental Affairs, commented: “The launch of ten23 health has a positive impact on our dynamic life sciences cluster by creating highly qualified jobs, leveraging local networks and adding to the increasing diversity of pharmaceutical and biotech companies and their strategic partners in our tri-national region.”
More information online
In this Edition Articles - Applications of Newly Developed 2.7 μm Porous Graphitic Carbon Particles in U/HPLC - Improve sensitivity and decrease matrix effects in pesticide residue analysis...
View all digital editions
Oct 31 2021 Philadelphia, PA, USA
Nov 02 2021 Johannesburg, South Africa
Nov 03 2021 Birmingham, UK
Nov 07 2021 Porto, Portugal
Nov 08 2021 Chiba, Japan